Lanthanum Carbonate (BAY77-1931)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia, Dialysis
Trial Timeline
Jun 1, 2005 → Oct 1, 2008
NCT ID
NCT00767637About Lanthanum Carbonate (BAY77-1931)
Lanthanum Carbonate (BAY77-1931) is a phase 2 stage product being developed by Bayer for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00767637. Target conditions include Hyperphosphatemia, Dialysis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01518387 | Phase 3 | Completed |
| NCT00767637 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperphosphatemia